DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI

Hematological Oncology ◽

10.1002/hon.100_2630 ◽

2019 ◽

Vol 37 ◽

pp. 291-292

Author(s):

R. Mazza ◽

M. Spina ◽

C. Califano ◽

F. Gaudio ◽

M. Carella ◽

...

Keyword(s):

Prospective Study ◽

Hodgkin Lymphoma ◽

Phase Ii ◽

Early Stage ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Dose Dense

Download Full-text

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

Annals of Hematology ◽

10.1007/s00277-021-04604-x ◽

2021 ◽

Author(s):

Armando Santoro ◽

Rita Mazza ◽

Michele Spina ◽

Catello Califano ◽

Giorgina Specchia ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Phase Ii Study ◽

Early Stage ◽

First Line ◽

Double Step ◽

First Line Therapy ◽

Line Therapy ◽

Dose Dense

Download Full-text

PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI

HemaSphere ◽

10.1097/01.hs9.0000563228.79887.e0 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 563-564

Author(s):

R. Mazza ◽

M. Spina ◽

C. Califano ◽

F. Gaudio ◽

M. Carella ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Early Stage ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Dose Dense ◽

Multi Center Study ◽

Center Study

Download Full-text

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

ESMO Open ◽

10.1016/j.esmoop.2021.100062 ◽

2021 ◽

Vol 6 (2) ◽

pp. 100062

Author(s):

J. Sastre ◽

P. García-Alfonso ◽

J.M. Viéitez ◽

M.T. Cano ◽

F. Rivera ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Wild Type ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BMC Cancer ◽

10.1186/s12885-015-1656-4 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 4

Author(s):

Jean-Baptiste Bachet ◽

◽

Benoist Chibaudel ◽

Franck Bonnetain ◽

Pierre Validire ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Pancreatic Cancer ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Download Full-text

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

British Journal of Cancer ◽

10.1038/bjc.2012.555 ◽

2013 ◽

Vol 108 (2) ◽

pp. 265-270 ◽

Cited By ~ 22

Author(s):

A Atmaca ◽

S-E Al-Batran ◽

D Werner ◽

C Pauligk ◽

T Güner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy

Download Full-text

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90703-8 ◽

2003 ◽

Vol 1 (5) ◽

pp. S202 ◽

Cited By ~ 15

Author(s):

J.-M. Extra ◽

F. Cognetti ◽

S. Chan ◽

D. Maraninchi ◽

R. Snyder ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Clinical & Translational Oncology ◽

10.1007/s12094-011-0637-6 ◽

2011 ◽

Vol 13 (3) ◽

pp. 179-184 ◽

Cited By ~ 51

Author(s):

Cristina Grávalos ◽

Carlos Gómez-Martín ◽

Fernando Rivera ◽

Inmaculada Alés ◽

Bernardo Queralt ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Gastroesophageal Junction Cancer ◽

Line Therapy

Download Full-text

Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study

Clinics and Research in Hepatology and Gastroenterology ◽

10.1016/j.clinre.2012.10.014 ◽

2013 ◽

Vol 37 (5) ◽

pp. 527-529 ◽

Cited By ~ 5

Author(s):

Bilal Ergül ◽

Erdem Koçak ◽

Adnan Taş ◽

Levent Filik ◽

Seyfettin Köklü

Keyword(s):

Prospective Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

H Pylori ◽

A Prospective Study

Download Full-text

Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy

Annals of Hematology ◽

10.1007/s00277-015-2529-2 ◽

2015 ◽

Vol 95 (1) ◽

pp. 1-9 ◽

Cited By ~ 23

Author(s):

Hugo J. A. Adams ◽

Rutger A. J. Nievelstein ◽

Thomas C. Kwee

Keyword(s):

Systematic Review ◽

Complete Remission ◽

Hodgkin Lymphoma ◽

Fdg Pet ◽

Prognostic Value ◽

Meta Analysis ◽

First Line ◽

First Line Therapy ◽

Remission Status ◽

Line Therapy

Download Full-text

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Journal of Hepatology ◽

10.1016/j.jhep.2011.07.033 ◽

2012 ◽

Vol 56 (2) ◽

pp. 486-487 ◽

Cited By ~ 6

Author(s):

Jairo A. Garcia ◽

Lewis R. Roberts

Keyword(s):

Hepatocellular Carcinoma ◽

Phase Ii ◽

Advanced Hepatocellular Carcinoma ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text